The connection between AR expression and cancer cell sensitivity to AA, suggested by our study and that of Wang et al. [80], could be pursued to develop novel combination therapies for AR-dependent tumors, including certain sub-types of triple negative breast cancer, and the early stage and castration-resistant phase of prostate cancer. The gene discussed is AR; the disease is prostate carcinoma.